Ignite Creation Date:
2024-05-06 @ 9:11 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02926638
Status:
TERMINATED
Last Update Posted:
2020-03-19
First Post:
2016-05-06
Brief Title:
Lung-MAP Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Stage IV Squamous Cell Lung Carcinoma AJCC v7 |
| MET Positive |
| Recurrent Squamous Cell Lung Carcinoma |
Keywords: